Glaxo Unit Viiv Gets FDA OK for 1st Injectable Treatment for HIV Pre-Exposure Prevention

 The U.S. Food and Drug Administration said Monday that it has approved Apretude, a drug by GlaxoSmithKline unit Viiv to reduce the risk of sexually acquired HIV.

Apretude is the first injectable pre-exposure prophylaxis for the virus that causes AIDS, the agency said.

"This injection, given every two months, will be critical to addressing the HIV epidemic in the U.S., including helping high-risk individuals and certain groups where adherence to daily medication has been a major challenge or not a realistic option," said Dr. Debra Birnkrant, director of the Division of Antivirals in the FDA's Center for Drug Evaluation and Research.

At-risk adults and adolescents weighing at least 77 pounds can use Apretude, the FDA said.

https://www.marketscreener.com/quote/stock/GLAXOSMITHKLINE-PLC-9590199/news/GlaxoSmithKline-Unit-Viiv-Gets-FDA-Approval-for-First-Injectable-Treatment-for-HIV-Pre-Exposure-Prev-37380567/